• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AV-TEMECULA-CT ABSORB GT1 BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE DRUG ELUTING SCAFFOLD

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AV-TEMECULA-CT ABSORB GT1 BIORESORBABLE VASCULAR SCAFFOLD SYSTEM; BIORESORBABLE DRUG ELUTING SCAFFOLD Back to Search Results
Catalog Number 1234300-18
Device Problem Difficult or Delayed Positioning (1157)
Patient Problem Hematoma (1884)
Event Date 12/15/2016
Event Type  Injury  
Manufacturer Narrative
(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.The scaffold remains in the patient.Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.
 
Event Description
It was reported that the procedure was to treat an 80% stenosis in the proximal left anterior descending artery.Pre-dilatation was performed and the 3.0 x 18 mm absorb gt1 scaffold was deployed and post-dilated with a non-compliant balloon.There were no issues deploying the scaffold; however, the scaffold still presented with a waist due to recoil.Additional post-dilatation was done with a 3.25 non-compliant balloon at 20 atmospheres, at which time an intramural hematoma occurred from the mid to distal below the lesion.Two drug eluting stents were implanted to resolve the urgent situation.The vessel flow is okay and the patient condition is fine.No additional information was provided.
 
Manufacturer Narrative
(b)(4).Product performance engineering reviewed the incident information; however, it was not possible to perform a thorough analysis on the product because it was not returned to abbott vascular for investigation.Based on the information reviewed, a conclusive cause for the difficult to deploy/recoil and patient effect cannot be determined.A review of the lot history record revealed no manufacturing nonconformities that would have contributed to this complaint.Additionally, a review of the complaint history identified no other similar incidents from this lot.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ABSORB GT1 BIORESORBABLE VASCULAR SCAFFOLD SYSTEM
Type of Device
BIORESORBABLE DRUG ELUTING SCAFFOLD
Manufacturer (Section D)
AV-TEMECULA-CT
abbott vascular
26531 ynez road
temecula CA 92591 4628
Manufacturer (Section G)
ABBOTT VASCULAR, TEMECULA, CA USA REG# 2024168
abbott vascular
26531 ynez road
temecula CA 92591 4628
Manufacturer Contact
connie speck
abbott vascular
26531 ynez road
temecula, CA 92591-4628
9519143996
MDR Report Key6243285
MDR Text Key64536106
Report Number2024168-2017-00316
Device Sequence Number1
Product Code PNY
Combination Product (y/n)N
Reporter Country CodeTW
PMA/PMN Number
P150023
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Health Professional
Remedial Action Other
Type of Report Initial,Followup
Report Date 01/24/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/11/2017
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date10/17/2017
Device Catalogue Number1234300-18
Device Lot Number6042161
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/23/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured04/01/2016
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age61 YR
-
-